Alembic Pharma — a 119-year-old company that once sold tinctures and now sells ANDAs like Big Bazaar discounts. Market cap ₹18,800 Cr, ROCE 13%, and a P/E that’s higher than your blood pressure after eating Gujarati farsan. With India formulations growing at 13%, US generics at 24%, and ex-US at 46%, Alembic is diversifying faster than your cousin switching careers from MBA to crypto to stand-up comedy. But with R&D spend dropping from 13% of revenue to just 8%, is Alembic really innovating, or just “cost-cutting with a lab coat on”?
2. Introduction
Alembic’s story is straight out of a Bollywood biopic: born in Baroda, survived multiple USFDA raids, grew into a global generics player, and still remains the 20th ranked player in India (1.4% market share). In other words: respected but not quite Sun Pharma.
It’s everywhere: India, US, Chile, Australia, Europe — literally, anywhere someone sneezes, Alembic wants to sell them an anti-infective. But the company’s charm lies in its “double life”:
At home, it’s a branded generics player with strong brands in cough & cold, cardiology, gynecology.
Abroad, it’s a hustler fighting in the US with ANDAs, Para IVs, and 163 products already commercialised.
They’ve cut R&D from 13% to 8% of revenues, while still filing 20+ ANDAs a year. This is like saying, “Bhai, main gym jaa raha hoon par sirf Sunday ko aur woh bhi light dumbbell se.”
So, is Alembic becoming lean and smart, or weak and under-prepared? Let’s audit.
3. Business Model – WTF Do They Even Do?
Alembic basically sells patented expired drugs in new bottles, while convincing regulators that they’re safe. In corporate-speak, it’s “formulations + APIs.”
Formulations (83% of revenue):
India (35%) – Strong in acute and specialty. Speciality now 54% of sales (gynecology, cardiology, diabetology), while acute fell from 33% → 27%. Basically, they’re moving from “fever tablets” to “lifetime diabetes customers.”
US (29%) – 163 products live, 16 launches in FY25, 15 more planned. Fighting Cipla, Zydus, Dr. Reddy’s in the brutal US generic price erosion jungle.
Ex-US (19%) – Growing faster than your Jio recharge pack: 46% growth in 2 years, thanks to EU, Canada, Australia, South Africa.
APIs (17%): Once a money-spinner, now a “meh” division — declined 3% in 2 years. 36% consumed in-house, rest sold. Reactor capacity 1,512 KL, 194 APIs manufactured. The “backward integration” is more like a backache.
R&D: 915 nerds filing ANDAs, but with less money. 266 ANDAs filed till FY25, 46 pending approvals. Oncology and ophthalmic pipelines look good, but let’s be honest — everyone’s doing the same.
Question: If Alembic spends less on R&D but still files ANDAs, is this jugaad efficiency or jugaad laziness?
